Vascular targeted nanotherapeutic approach for obesity treatment

References

• ApovianCMRiffenburgKMPerspectives on the global obesity epidemicCurr Opin Endocrinol Diabetes Obes201724530730928841635
   PubMedGoogle Scholar
• EckelRHKahnSEFerranniniEObesity and Type 2 Diabetes: What can be unified and what needs to be individualized?J Clin Endocrinol Metab20119661654166321602457
   PubMed Web of Science ®Google Scholar
• LavieCJMilaniRVVenturaHOObesity and cardiovascular disease: risk factor, paradox, and impact of weight lossJ Am Coll Cardiol200953211925193219460605
   PubMed Web of Science ®Google Scholar
• BrayGAThe underlying basis for obesity: relationship to cancerJ Nutr200213211 Suppl3451S3455S12421869
   PubMed Web of Science ®Google Scholar
• NarkiewiczKObesity and hypertension – the issue is more complex than we thoughtNephrology Dialysis Transplantation2006212264267
   PubMed Web of Science ®Google Scholar
• BrayGAA concise review on the therapeutics of obesityNutrition2000161095396011054601
   PubMed Web of Science ®Google Scholar
• CannonCPKumarATreatment of overweight and obesity: Lifestyle, pharmacologic, and surgical optionsClin Cornerstone200994557119789064
   PubMedGoogle Scholar
• van GaalLDirinckEPharmacological Approaches in the Treatment and Maintenance of Weight LossDiabetes Care201639Suppl 2S260S26727440841
   PubMedGoogle Scholar
• AdanRAHMechanisms underlying current and future anti-obesity drugsTrends Neurosci201336213314023312373
   PubMed Web of Science ®Google Scholar
• KangJGParkC-YAnti-obesity drugs: a review about their effects and safetyDiabetes Metab J2012361132522363917
   PubMedGoogle Scholar
• Ioannides-DemosLLPiccennaLMcneilJJPharmacotherapies for obesity: past, current, and future therapiesJ Obes2011201115118
   Google Scholar
• WilliamsGWithdrawal of sibutramine in EuropeBMJ20103403c82420144986
   PubMedGoogle Scholar
• AbbotAbbott to voluntarily withdraw Meridia® (Sibutramine) in the U.S.10102010 Available from: http://www.disabled-world.com/medical/recalls/meridia-sibutramine-withdraw.php#ixzz28ih0rGMMAccessed November 30, 2017
   Google Scholar
• MedsafeWithdrawal of Sibutramine (Reductil) in New Zealand10112010 Available from: http://www.medsafe.govt.nz/hot/media/2010/SibutramineOct2010.aspAccessed November 30, 2017
   Google Scholar
• Therapeutic Goods AdministrationSibutramine (Reductil) – withdrawal in Australia1082010 Available from: http://www.tga.gov.au/safety/alerts-medicine-sibutramine-101008.htmAccessed November 30, 2017
   Google Scholar
• KoloninMGSahaPKChanLPasqualiniRArapWReversal of obesity by targeted ablation of adipose tissueNat Med200410662563215133506
   PubMed Web of Science ®Google Scholar
• HossenMNKajimotoKAkitaHHyodoMIshitsukaTHarashimaHLigand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissueJ Control Release2010147226126820647023
   PubMed Web of Science ®Google Scholar
• HossenMNKajimotoKAkitaHHyodoMHarashimaHA comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medicationJ Control Release2013171210411223871959
   PubMed Web of Science ®Google Scholar
• ArnerPObesity – a genetic disease of adipose tissue?Br J Nutr200083S1S9S1610889786
   PubMedGoogle Scholar
• O’RahillySFarooqiISGshYChallisBGHuman obesity-lessons from monogenic disordersEndocrinology20031443757376412933645
   PubMed Web of Science ®Google Scholar
• TrayhurnPAdipocyte biologyObes Rev20078s14144
   PubMedGoogle Scholar
• RacetteSBDeusingerSSDeusingerRObesity: Overview of prevalence, etiology, and treatmentPhysical Therapy200383327628812620091
   PubMed Web of Science ®Google Scholar
• PulgarónERChildhood obesity: a review of increased risk for physical and psychological comorbiditiesClin Ther2013351A18A3223328273
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO)Global Health Observatory (GHO) data2017 Available from: http://www.who.int/gho/ncd/risk_factors/overweight_obesity/obesity_adults/en/Accessed June 4, 2018
   Google Scholar
• World Health Organization (WHO)Global Health Observatory data repositoryPrevalence of obesity among adults, BMI ≥ 30 age-standardized. Estimates by WHO region Available from: http://apps.who.int/gho/data/view.main.REGION2480A?lang=enAccessed June 4, 2018
   Google Scholar
• Department of Health (South Africa)World Obesity Day 20162016 Available from: http://www.health.gov.za/index.php/gf-tb-program/323-world-obesity-day-2016Accessed November 20, 2017
   Google Scholar
• IwenKAHPerwitzNKrausDFasshauerMKleinJPutting fat cells onto the road map to novel therapeutic strategiesDiscov Med20066758117234130
   PubMedGoogle Scholar
• GustafsonBHammarstedtAAnderssonCXSmithUTissueIAA Culprit Underlying the Metabolic Syndrome and AtherosclerosisArterioscler Thromb Vasc Biol2007272276228317823366
   PubMed Web of Science ®Google Scholar
• HaunerHThe new concept of adipose tissue functionPhysiol Behav200483465365815621071
   PubMed Web of Science ®Google Scholar
• HausmanDBDigirolamoMBartnessTJHausmanGJMartinRJThe biology of white adipocyte proliferationObes Rev20012423925412119995
   PubMedGoogle Scholar
• Vázquez-VelaMEFTorresNTovarARWhite adipose tissue as endocrine organ and its role in obesityArch Med Res200839871572818996284
   PubMed Web of Science ®Google Scholar
• BozaogluKCurranJEStockerCJChemerin, a Novel Adipokine in the Regulation of AngiogenesisJ Clin Endocrinol Metab20109552476248520237162
   PubMed Web of Science ®Google Scholar
• HajerGRvan HaeftenTWVisserenFLJAdipose tissue dysfunction in obesity, diabetes, and vascular diseasesEur Heart J200829242959297118775919
   PubMed Web of Science ®Google Scholar
• KrugAWEhrhart-BornsteinMNewly discovered endocrine functions of white adipose tissue: possible relevance in obesity-related diseasesCell Mol Life Sci200562121359136215924267
   PubMed Web of Science ®Google Scholar
• SethiJKVidal-PuigAJAdipose tissue function and plasticity orchestrate nutritional adaptationJ Lipid Res2007481253126217374880
   PubMed Web of Science ®Google Scholar
• Guerre-MilloMAdipose tissue and adipokines: for better or worseDiabetes Metab2004301131915029093
   PubMed Web of Science ®Google Scholar
• LefterovaMILazarMANew developments in adipogenesisTrends in Endocrinol Metab200920310711419269847
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research GroupReduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminN Engl J Med Overseas Ed20023466393403
   PubMed Web of Science ®Google Scholar
• KleinSSheardNFPi-SunyerXWeight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategiesDiabetes Care2004272067207315277443
   PubMed Web of Science ®Google Scholar
• WaddenTAMcguckinBGRothmanRASargentSLLifestyle modification in the management of obesityJ Gastrointest Surg20037445246312763398
   PubMed Web of Science ®Google Scholar
• HainerVToplakHMitrakouATreatment modalities of obesityDiabetes Care200831S269S27718227496
   PubMed Web of Science ®Google Scholar
• DemariaEJBariatric Surgery for Morbid ObesityN Engl J Med Overseas Ed20073562121762183
   PubMed Web of Science ®Google Scholar
• FisherBLSchauerPMedical and surgical options in the treatment of severe obesityAm J Surg20021846BS9S16
   PubMed Web of Science ®Google Scholar
• Foster-SchubertKECummingsDEEmerging Therapeutic Strategies for ObesityEndocr Rev200627777979317122357
   PubMed Web of Science ®Google Scholar
• AbellTLMinochaAGastrointestinal complications of bariatric surgery: diagnosis and therapyAm J Med Sci2006331421421816617237
   PubMed Web of Science ®Google Scholar
• BergerJRThe Neurological Complications of Bariatric SurgeryArch Neurol20046181185118915313834
   PubMedGoogle Scholar
• St JeorSTHaymanLLDanielsSRPrevention conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group II: age-dependent risk factors for obesity and comorbiditiesCirculation200411018e471e47515520331
   PubMed Web of Science ®Google Scholar
• GuptaKZhangJAngiogenesis: a curse or cure?Postgrad Med J20058195423624215811887
   PubMed Web of Science ®Google Scholar
• GriffioenAWMolemaGAngiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammationPharmacol Rev20005223726710835101
   PubMed Web of Science ®Google Scholar
• LiekensSde ClercqENeytsJAngiogenesis: regulators and clinical applicationsBiochem Pharmacol200161325327011172729
   PubMed Web of Science ®Google Scholar
• GoligorskyMSEndothelial cell dysfunction: can’t live with it, how to live without itAm J Physiol Renal Physiol20052885F871F88015821252
   PubMed Web of Science ®Google Scholar
• SengenèsCMiranvilleALolmèdeKCuratCABouloumiéAThe role of endothelial cells in inflamed adipose tissueJ Intern Med2007262441542117875177
   PubMed Web of Science ®Google Scholar
• CaballeroAEEndothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart diseaseObes Res200311111278128914627747
   PubMedGoogle Scholar
• SinghDKWinocourPFarringtonKReview: Endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetesBr J Diabetes Vasc Dis20101027177
   Google Scholar
• MatherKJSteinbergHOBaronADWeight loss and endothelial function in obesityDiabetes Care20032661927192812766136
   PubMed Web of Science ®Google Scholar
• MuellerJGaertnerFCBlechertBJanssenKPEsslerMTargeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivoMol Cancer Res2009771078108519584266
   PubMed Web of Science ®Google Scholar
• WangZDabrosinCYinXBroad targeting of angiogenesis for cancer prevention and therapySemin Cancer Biol201535S224S24325600295
   PubMed Web of Science ®Google Scholar
• NingY-MGulleyJLArlenPMPhase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerJ Clin Oncol201028122070207620308663
   PubMed Web of Science ®Google Scholar
• RosenLAntiangiogenic strategies and agents in clinical trialsOncologist2000590001202710804087
   PubMedGoogle Scholar
• TassiEWellsteinATumor Angiogenesis: Initiation and Targeting – Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal AdenocarcinomasCancer Res Treat200638418919719771241
   PubMedGoogle Scholar
• OkajiYTsunoNHSaitoSVaccines targeting tumour angiogenesis – a novel strategy for cancer immunotherapyEur J Surg Oncol200632436337016520018
   PubMed Web of Science ®Google Scholar
• GotoHYanoSMatsumoriYOgawaHBlakeyDCSoneSSensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatinClin Cancer Res200410227671767615570000
   PubMed Web of Science ®Google Scholar
• LiuYDeisserothATumor vascular targeting therapy with viral vectorsBlood200610783027303316373660
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature2000407680124925711001068
   PubMed Web of Science ®Google Scholar
• DaquinagACZhangYKoloninMGVascular targeting of adipose tissue as an anti-obesity approachTrends Pharmacol Sci201132530030721349592
   PubMed Web of Science ®Google Scholar
• CaoYAdipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseasesNat Rev Drug Discov20109210711520118961
   PubMed Web of Science ®Google Scholar
• ChristiaensVLijnenHRAngiogenesis and development of adipose tissueMol Cell Endocrinol20103181–22919686803
   PubMed Web of Science ®Google Scholar
• BråkenhielmECaoRGaoBAngiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in miceCirc Res200494121579158815155527
   PubMed Web of Science ®Google Scholar
• RupnickMAPanigrahyDZhangCYAdipose tissue mass can be regulated through the vasculatureProc Natl Acad Sci U S A20029916107301073512149466
   PubMed Web of Science ®Google Scholar
• KimYMAnJJJinY-JAssessment of the anti-obesity effects of the TNP-470 analog, CKD-732J Mol Endocrinol200738445546517446235
   PubMed Web of Science ®Google Scholar
• TamJDudaDGPerentesJYQuadriRSFukumuraDJainRKBlockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cellsPLoS One200943e497419333381
   PubMed Web of Science ®Google Scholar
• ThuaudFRibeiroNNebigilCGDésaubryLProhibitin ligands in cell death and survival: mode of action and therapeutic potentialChem Biol201320331633123521790
   PubMedGoogle Scholar
• KoushyarSJiangWGDartDAUnveiling the potential of prohibitin in cancerCancer Lett2015369231632226450374
   PubMed Web of Science ®Google Scholar
• MishraSNyombaBLGProhibitin – At the crossroads of obesity-linked diabetes and cancerExp Biol Med20172421111701177
   Web of Science ®Google Scholar
• AndeSRNguyenKHNyombaBLGMishraSProhibitin in Adipose and Immune FunctionsTrends Endocrinol Metab201627853154127312736
   PubMed Web of Science ®Google Scholar
• ChowdhuryIThompsonWEThomasKProhibitins role in cellular survival through Ras-Raf-MEK-ERK pathwayJ Cell Physiol20142298998100424347342
   PubMed Web of Science ®Google Scholar
• DongWQChaoMLuQHProhibitin overexpression improves myocardial function in diabetic cardiomyopathyOncotarget201671668026623724
   PubMedGoogle Scholar
• GiannottaMFragassiGTamburroAVanessaCLuiniASalleseMProhibitin: A novel molecular player in KDEL receptor signallingBiomed Res Int2015201573194541326064897
   PubMedGoogle Scholar
• CaoYLiangHZhangFProhibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancerJ Exp Clin Cancer Res201635356827084680
   PubMedGoogle Scholar
• HanJZhaoQBasmadjianCDésaubryLTheissALFlavaglines ameliorate experimental colitis and protect against intestinal epithelial cell apoptosis and mitochondrial dysfunctionInflamm Bowel Dis2016221556726398710
   PubMed Web of Science ®Google Scholar
• BasmadjianCThuaudFRibeiroNDésaubryLFlavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4AFuture Med Chem20135182185219724261894
   PubMed Web of Science ®Google Scholar
• ChenDChenFLuXIdentification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technologyInt J Oncol201037235536520596663
   PubMed Web of Science ®Google Scholar
• SibuyiNRThovhogiNGabuzaKBPeptide-functionalized nanoparticles for the selective induction of apoptosis in target cellsNanomedicine201712141631164528635372
   PubMed Web of Science ®Google Scholar
• HossenMNKajimotoKAkitaHHyodoMHarashimaHVascular-targeted nanotherapy for obesity: Unexpected passive targeting mechanism to obese fat for the enhancement of active drug deliveryJ Control Release2012163210111022982237
   PubMed Web of Science ®Google Scholar
• ThovhogiNSibuyiNMeyerMOnaniMMadieheATargeted delivery using peptide-functionalised gold nanoparticles to white adipose tissues of obese ratsJ Nanopart Res2015172112
   Web of Science ®Google Scholar
• BarnhartKFChristiansonDRHanleyPWA peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysSci Transl Med20113108108ra112-112
   Web of Science ®Google Scholar
• RuoslahtiETargeting tumor vasculature with homing peptides from phage displaySemin Cancer Biol200010643544211170865
   PubMed Web of Science ®Google Scholar
• StrimbuKTavelJAWhat are biomarkers?Curr Opin HIV AIDS20105646346620978388
   PubMed Web of Science ®Google Scholar
• ByrnesSAWeiglBHSelecting analytical biomarkers for diagnostic applications: a first principles approachExpert Rev Mol Diagn2018181192629200322
   PubMed Web of Science ®Google Scholar
• GerberDETargeted therapies: A new generation of cancer treatmentAm Fam Physician20087731131918297955
   PubMed Web of Science ®Google Scholar
• HilgenbrinkARLowPSFolate receptor-mediated drug targeting: from therapeutics to diagnosticsJ Pharm Sci200594102135214616136558
   PubMed Web of Science ®Google Scholar
• PalDNayakAKNanotechnology for targeted delivery in cancer therapeuticsInt J Pharm Sci Rev Res2010117
   Google Scholar
• ProvenzaleJMSilvaGAUses of nanoparticles for central nervous system imaging and therapyAJNR Am J Neuroradiol20093071293130119617446
   PubMed Web of Science ®Google Scholar
• MoghimiSMHunterACMurrayJCNanomedicine: current status and future prospectsThe FASEB Journal200519331133015746175
   PubMed Web of Science ®Google Scholar
• HardmanRA toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factorsEnviron Health Perspect2006114216517216451849
   PubMed Web of Science ®Google Scholar
• de JongWHHagensWIKrystekPBurgerMCSipsAJAMGeertsmaREParticle size-dependent organ distribution of gold nanoparticles after intravenous administrationBiomaterials200829121912191918242692
   PubMed Web of Science ®Google Scholar
• PraetoriusNMandalTEngineered nanoparticles in cancer therapyRecent Pat Drug Deliv Formul200711375119075873
   PubMedGoogle Scholar
• ShangLNienhausKNienhausGUEngineered nanoparticles interacting with cells: size mattersJ Nanobiotechnology2014147731551215
   Google Scholar
• BoboDRobinsonKJIslamJThurechtKJCorrieSRNanoparticle-based medicines: A review of FDA-approved materials and clinical trials to datePharm Res201633102373238727299311
   PubMed Web of Science ®Google Scholar
• WangECWangAZNanoparticles and their applications in cell and molecular biologyIntegr Biol201461926
   Google Scholar
• KingsleyJDDouHMoreheadJRabinowBGendelmanHEDestacheCJNanotechnology: A Focus on Nanoparticles as a Drug Delivery SystemJ Neuroimmune Pharmacol20061334035018040810
   PubMed Web of Science ®Google Scholar
• BazakRHouriMEl AchySKamelSRefaatTCancer active targeting by nanoparticles: a comprehensive review of literatureJ Cancer Res Clin Oncol2015141576978425005786
   PubMed Web of Science ®Google Scholar
• YezhelyevMVGaoXXingYAl-HajjANieSO’ReganRMEmerging use of nanoparticles in diagnosis and treatment of breast cancerLancet Oncol20067865766716887483
   PubMed Web of Science ®Google Scholar
• OjedaRde PazJLBarrientosAGMartín-LomasMPenadésSPreparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccinesCarbohydr Res20073423–444845917173881
   PubMed Web of Science ®Google Scholar
• TomuleasaCSoritauOOrzaAGold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cellsJ Gastrointestin Liver Dis20122118719622720309
   PubMed Web of Science ®Google Scholar
• BriggerIDubernetCCouvreurPNanoparticles in cancer therapy and diagnosisAdv Drug Deliv Rev200254563165112204596
   PubMed Web of Science ®Google Scholar
• CaruthersSDWicklineSALanzaGMNanotechnological applications in medicineCurr Opin Biotechnol2007181263017254762
   PubMed Web of Science ®Google Scholar
• XueYXuXZhangXQFarokhzadOCLangerRPreventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticlesProc Natl Acad Sci U S A2016113205552555727140638
   PubMed Web of Science ®Google Scholar
• AnselmoACMitragotriSNanoparticles in the clinicBioeng Transl Med201611102929313004
   PubMed Web of Science ®Google Scholar
• PillaiGNanomedicines for cancer therapy: An update of FDA approved and those under various stages of developmentSOJ Pharm Pharm Sci20141213
   Google Scholar
• AnselmoACMitragotriSA Review of clinical translation of inorganic nanoparticlesAaps J20151751041105425956384
   PubMed Web of Science ®Google Scholar
• PengXMehtaRGDifferential expression of prohibitin is correlated with dual action of Vitamin D as a proliferative and antiproliferative hormone in breast epithelial cellsJ Steroid Biochem Mol Biol20071033–544645017207617
   PubMed Web of Science ®Google Scholar
• MalinowskiJMBolestaSRosiglitazone in the treatment of type 2 diabetes mellitus: a critical reviewClin Ther200022101151116811110228
   PubMed Web of Science ®Google Scholar
• LeePGreenfieldJRHoKKFulhamMJA critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humansAm J Physiol Endocrinol Metab20102994E601E60620606075
   PubMed Web of Science ®Google Scholar
• WuJBoströmPSparksLMBeige adipocytes are a distinct type of thermogenic fat cell in mouse and humanCell2012150236637622796012
   PubMed Web of Science ®Google Scholar
• LinJZMartagónAJCiminiSLPharmacological Activation of Thyroid Hormone Receptors Elicits a Functional Conversion of White to Brown FatCell Rep20151381528153726586443
   PubMed Web of Science ®Google Scholar
• KieferFWThe significance of beige and brown fat in humansEndocr Connect201765R70R7928465400
   PubMed Web of Science ®Google Scholar